RESISTANCE MECHANISMS TO FIRST LINE DRUG IN MYCOBACTERIUM TUBERCULOSIS: A REVIEW

The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, identified as resistant to at least isoniazid and rifampin, these two drugs form the backbone of the first line drug which is used for tuberculosis (TB) treatment, unresponsive has hampered TB control. As a...

Full description

Bibliographic Details
Main Authors: Jabbar S. Hassan, Bushra J. Al-Tamimi, Thanaa R. Abdulrahman, Qudas W. Jamal
Format: Article
Language:English
Published: Al-Nahrain University/College of medicine 2022-06-01
Series:The Iraqi Journal of Medical Sciences
Online Access:https://www.iraqijms.net/index.php?do=view&type=article&id=810
_version_ 1817978742532734976
author Jabbar S. Hassan
Bushra J. Al-Tamimi
Thanaa R. Abdulrahman
Qudas W. Jamal
author_facet Jabbar S. Hassan
Bushra J. Al-Tamimi
Thanaa R. Abdulrahman
Qudas W. Jamal
author_sort Jabbar S. Hassan
collection DOAJ
description The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, identified as resistant to at least isoniazid and rifampin, these two drugs form the backbone of the first line drug which is used for tuberculosis (TB) treatment, unresponsive has hampered TB control. As a result of the nearly universal calculation of with half a million new cases of MDR/first line drug TB per year, it is important to keep the database up to date awareness of the processes that contribute to the emergence of MDR Mtb. This resistance is produced for a variety of reasons, including genetic, microbiological factors, non-adherence to treatment by patients and/or failures in therapy administration by some referrer medical centre for TB. This review offers a detailed summary of genetic mechanisms that lead to resistant to first line drug therapy used in management of TB as well as up-to-date information on some new aspects lead to such problem. Keywords: Mycobacterium tuberculosis, first line drug, anti-TB treatment, World Health Organization, isoniazid and rifampin Citation: Hassan JS, Al-Tamimi BJ, Abdulrahman TR, Jamal QW. Resistance mechanisms to first line drug in Mycobacterium tuberculosis: A review. Iraqi JMS. 2022; 20(1): 35-43. doi: 10.22578/IJMS.20.1.5
first_indexed 2024-04-13T22:33:11Z
format Article
id doaj.art-3019547c53f64f0abc0f9f71b21e98c3
institution Directory Open Access Journal
issn 1681-6579
2224-4719
language English
last_indexed 2024-04-13T22:33:11Z
publishDate 2022-06-01
publisher Al-Nahrain University/College of medicine
record_format Article
series The Iraqi Journal of Medical Sciences
spelling doaj.art-3019547c53f64f0abc0f9f71b21e98c32022-12-22T02:26:51ZengAl-Nahrain University/College of medicineThe Iraqi Journal of Medical Sciences1681-65792224-47192022-06-01201354310.22578/IJMS.20.1.5RESISTANCE MECHANISMS TO FIRST LINE DRUG IN MYCOBACTERIUM TUBERCULOSIS: A REVIEWJabbar S. HassanBushra J. Al-TamimiThanaa R. AbdulrahmanQudas W. Jamal The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, identified as resistant to at least isoniazid and rifampin, these two drugs form the backbone of the first line drug which is used for tuberculosis (TB) treatment, unresponsive has hampered TB control. As a result of the nearly universal calculation of with half a million new cases of MDR/first line drug TB per year, it is important to keep the database up to date awareness of the processes that contribute to the emergence of MDR Mtb. This resistance is produced for a variety of reasons, including genetic, microbiological factors, non-adherence to treatment by patients and/or failures in therapy administration by some referrer medical centre for TB. This review offers a detailed summary of genetic mechanisms that lead to resistant to first line drug therapy used in management of TB as well as up-to-date information on some new aspects lead to such problem. Keywords: Mycobacterium tuberculosis, first line drug, anti-TB treatment, World Health Organization, isoniazid and rifampin Citation: Hassan JS, Al-Tamimi BJ, Abdulrahman TR, Jamal QW. Resistance mechanisms to first line drug in Mycobacterium tuberculosis: A review. Iraqi JMS. 2022; 20(1): 35-43. doi: 10.22578/IJMS.20.1.5https://www.iraqijms.net/index.php?do=view&type=article&id=810
spellingShingle Jabbar S. Hassan
Bushra J. Al-Tamimi
Thanaa R. Abdulrahman
Qudas W. Jamal
RESISTANCE MECHANISMS TO FIRST LINE DRUG IN MYCOBACTERIUM TUBERCULOSIS: A REVIEW
The Iraqi Journal of Medical Sciences
title RESISTANCE MECHANISMS TO FIRST LINE DRUG IN MYCOBACTERIUM TUBERCULOSIS: A REVIEW
title_full RESISTANCE MECHANISMS TO FIRST LINE DRUG IN MYCOBACTERIUM TUBERCULOSIS: A REVIEW
title_fullStr RESISTANCE MECHANISMS TO FIRST LINE DRUG IN MYCOBACTERIUM TUBERCULOSIS: A REVIEW
title_full_unstemmed RESISTANCE MECHANISMS TO FIRST LINE DRUG IN MYCOBACTERIUM TUBERCULOSIS: A REVIEW
title_short RESISTANCE MECHANISMS TO FIRST LINE DRUG IN MYCOBACTERIUM TUBERCULOSIS: A REVIEW
title_sort resistance mechanisms to first line drug in mycobacterium tuberculosis a review
url https://www.iraqijms.net/index.php?do=view&type=article&id=810
work_keys_str_mv AT jabbarshassan resistancemechanismstofirstlinedruginmycobacteriumtuberculosisareview
AT bushrajaltamimi resistancemechanismstofirstlinedruginmycobacteriumtuberculosisareview
AT thanaarabdulrahman resistancemechanismstofirstlinedruginmycobacteriumtuberculosisareview
AT qudaswjamal resistancemechanismstofirstlinedruginmycobacteriumtuberculosisareview